Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: or therapy0-- -?

Viralgen Teams with Elaaj Bio to Advance CDKL5 Deficiency Gene Therapy

Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development...

Amazon Pharmacy Expands Same-Day Delivery and Kiosk Access for New Ozempic® Pill

Amazon Pharmacy a full-service digital pharmacy that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will...

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the...

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

YARAL Pharma Inc. the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now...

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

SQ Innovation, developer of Lasix® ONYU, announced two important regulatory milestones in its international expansion strategy: the receipt of a CE marking certificate for the Lasix ONYU device, and the acceptance of Lasix ONYU by the European...

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced new clinical data demonstrating a significant association between femoral subchondral bone shape, measured by B-score, and meniscal pathology in patients with knee...

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal...

Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure

Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of...

Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh...

Emerging From Stealth, Oryon Cell Therapies Targets Autologous Neuron Replacement for Parkinson’s Disease and Neurodegenerative Disorders

Oryon Cell Therapies a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21...

Neurizon Begins Dosing of NUZ-001 in HEALEY ALS Platform Trial

Neurizon® Therapeutics Limited a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS...

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

KORU Medical Systems, Inc. a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, announced that the Company received...

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals Holding Corp. a fully integrated, commercial biotechnology company, presented data on TONMYA™, which was investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit, on January 29, 2026, in Boston,...

Align Technology Supports Children and Teens With 30 Invisalign® Treatments via Smiles4Canada Program

Align Technology, Inc. a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative...

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Shanghai Ark Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) for...

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced positive results of an investigator-initiated...

Within one year of its launch, L&C Bio's 'Re2O' has emerged as a leading procedure in K-Medical Tourism

This growth is particularly remarkable considering that Re2O had relatively low brand recognition only six months ago. Dermatology and plastic surgery clinics, as well as major university hospitals across Korea, have recently accelerated adoption...

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals plc announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and...

Results 21 - 40 of 104